NIVOLUMAB AND RELATLIMAB-RMBW (OPDUALAG) Nursing Considerations

What is the generic name?

NIVOLUMAB AND RELATLIMAB-RMBW

What is the Trade Name for NIVOLUMAB AND RELATLIMAB-RMBW?

OPDUALAG

What are the Indications for NIVOLUMAB AND RELATLIMAB-RMBW?

• 1 INDICATIONS AND USAGE OPDUALAG‚Ñ¢ is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. OPDUALAG is a combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. (1)

References: https://open.fda.gov/